Lactoferrin Gut Health Meta-analysis: What the Evidence Says

Quick Answer

Lactoferrin Gut Health Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• While advances in perinatal medicine and neonatal intensive care have significantly improved the survival rates of preterm infants, this progress has been accompanied by a rise in the incidence of NEC, with a global prevalence of approximately 7.0% among infants with extremely low birth weight (ELBW). [Chen Siyi (2026); evidence level 3]
• The precise etiology and pathogenesis of NEC remain incompletely understood; it is generally posited to be associated with multiple factors, such as intestinal barrier immaturity in preterm infants, gut microbiota dysbiosis, inappropriate feeding practices, and abnormal inflammatory responses. [Chen Siyi (2026); evidence level 3]
• Based on current research evidence, this review comprehensively examines the health value of dairy products across four dimensions: nutritional components, core mechanisms, disease-preventive effects, and synergistic interactions, aiming to inform the development of scientific dietary guidelines and clinical nutrition interventions. [Wang Miao (2026); evidence level 4]
• By integrating findings from epidemiological surveys, clinical trials, and molecular biology research, this study critically evaluates the potential of dairy products in mitigating chronic disease risk and clearly distinguishes the evidence hierarchy amongexperiments, animal models, and human studies. [Wang Miao (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For lactoferrin gut health meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Chen Siyi (2026). Synergistic regulation of gut microbiota and metabolites by breast milk and probiotics in the prevention of neonatal necrotizing enterocolitis: mechanisms and prospects. DOI: 10.21037/tp-2025-1-913. PMCID: PMC13181626. PMID: 42158666. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13181626/
• Wang Miao (2026). A narrative review of nutritional components, health effects, and disease prevention mechanisms of dairy products. DOI: 10.3389/fpubh.2026.1799734. PMCID: PMC13099306. PMID: 42027937. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13099306/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.